Immunotherapy for prostate cancer: recent developments and future challenges
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10555-013-9479-8.pdf
Reference120 articles.
1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63(1), 11–30. doi: 10.3322/caac.21166 .
2. Huggins, C., & Hodges, C. V. (2002). Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 168(1), 9–12.
3. Schweizer, M. T., & Antonarakis, E. S. (2012). Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol, 4(4), 167–178. doi: 10.1177/1756287212452196 .
4. Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 26(7), 1148–1159. doi: 10.1200/jco.2007.12.4487 .
5. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351(15), 1502–1512. doi: 10.1056/NEJMoa040720 .
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Revolutionizing of bioactive natural products in prostate cancer research and care: Promising discoveries and future directions;Intelligent Pharmacy;2024-07
2. Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer;Epigenetic Regulation of Cancer - Part A;2023
3. Immunotoxins and Their Role in Prostate Cancer Treatment;Clinical Cancer Investigation Journal;2023
4. Neoplasms of the Prostate;Holland‐Frei Cancer Medicine;2022-10-21
5. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer;Communications Biology;2022-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3